Abstract 267P
Background
Homologous recombination deficiency (HRD) score serves as a promising biomarker to identify patients who are eligible for treatment with PARP inhibitor (PARPi). Previous studies have suggested a 3-biomarker Genomic Instability Score (GIS) threshold of ≥42 is a valid biomarker to predict response to PARPi in patients with ovarian cancer. However, the GIS threshold for prostate cancer (PCa) is still lacking. Here, we conducted an exploratory analysis to investigate an appropriate GIS score and to evaluate its ability to predict response to PARPi in prostate cancer patients.
Methods
A total of 225 patients with PCa were included in this study. Tumor tissue specimens were collected for targeted next-generation sequencing for homologous recombination repair (HRR) genes and promoter methylation analysis. GIS score was calculated based on over 50,000 single-nucleotide polymorphisms (SNP) distributed across the human genome, incorporating three SNP-based assays: loss of heterozygosity, telomeric allelic imbalance, and large-scale state transition. The HRD score threshold was set at the 5th percentile of the GIS scores in our cohort of known BRCA1/2-deficient tumors which is the method used to define the HRD threshold in breast and ovarian cancer.
Results
In our cohort, 22 patients (9.78%) had BRCA1/2 mutations or BRCA1/2 promoter methylation, with additional 32 patients (14.22%) carrying mutations in HRR genes. The median HRD score was 2 (ranged from 0 to 78) in total cohort which is much lower than that of in breast and ovarian cancer. The 5th percentile of HRD scores was 9 in the BRCA1/2-deficient cohort and consequently high HRD was defined as HRD scores >9. In the 12 patients who received PARPi in our cohort, 8 patients with a high HRD score achieved a disease control rate of 83.3%. In addition, 4 patients with a low HRD score but with mutations in HRR genes other than BRCA1/2 achieved a disease control rate of 25.0%.
Conclusions
HRD positive, defined as GIS score >9, may be an appropriate threshold to predict the likelihood of response to PARPi in prostate cancer. Prospective, and large sample clinical trials will be needed to confirm our findings.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
J. Wang.
Funding
China Anti-Cancer Association-Hengrui PARP Inhibitor Cancer Research Fund (Phase I).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
271P - Prostate cancer with histone modifier UTX mutations can benefit from olaparib
Presenter: NOBUHITO MURAMOTO
Session: Poster Display
Resources:
Abstract
272P - Comparison between MRI-targeted and standard biopsy for prostate cancer detection: A systematic review and meta-analysis
Presenter: Andree Kurniawan
Session: Poster Display
Resources:
Abstract
273P - The diagnostic performance of cognitive MRI-targeted biopsy in biopsy-naïve patients undergoing systematic 14-region 18-core biopsy: Do the three areas affect the results?
Presenter: Yuka Toyama
Session: Poster Display
Resources:
Abstract
274P - Index tumor location influencing early biochemical recurrence after radical prostatectomy in patients with negative surgical margins
Presenter: Jun Akatsuka
Session: Poster Display
Resources:
Abstract
275P - Prognosis of metastatic castration-resistant prostate cancer in response to chemotherapy and PSMA expression in circulating tumor cells
Presenter: Naoya Nagaya
Session: Poster Display
Resources:
Abstract
276P - Prognostic significance of p53 mutation in metastatic hormone-sensitive prostate cancer
Presenter: Lakshmi Kamala
Session: Poster Display
Resources:
Abstract
277P - Vasohibin-1 expression as a biomarker of aggressive growth in prostate ductal adenocarcinoma
Presenter: Murad Salomov
Session: Poster Display
Resources:
Abstract
278P - Full-coverage radiotherapy for prostate cancer patients with oligometastases
Presenter: Bichun Xu
Session: Poster Display
Resources:
Abstract
279P - Hypofractionated radiotherapy protocol implementation and early outcomes for prostate cancer patients: A single institution retrospective review
Presenter: Thu Nguyen
Session: Poster Display
Resources:
Abstract
280P - Radium-223 for patients with metastatic castration-resistant prostate cancer with symptomatic bone metastases progressing after first-line abiraterone or enzalutamide: One institutional experience
Presenter: Keng Man Chiang
Session: Poster Display
Resources:
Abstract